Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
This study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen.
Age
18–45
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Participant either must have ceased lactating at screening or, if still lactating or actively breastfeeding at screening, must agree to temporarily cease giving breast milk to her infant(s)
Participant has had a Major Depressive Episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 Axis I Disorders (SCID-I)
Participant was \<=six months postpartum.
You may not be if
Active psychosis
Attempted suicide associated with current episode of postpartum depression
Medical history of seizures
Medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.
Clareo Health | A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression
